Philipp Keyl

Philipp Keyl

Auto-generated profile, based on publicly available information

Philipp Keyl

Institute of Pathology, Ludwig-Maximilians-University Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JKJulius Keyl
Julius Keyl
PKPhilipp Keyl
Philipp Keyl
GMGrégoire Montavon
Grégoire Montavon
RHRené Hosch
René Hosch
ABAlexander Brehmer
Alexander Brehmer
JKJens Kleesiek
Jens Kleesiek
Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation, we combined multimodal real-world data and explainable artificial intelligence (xAI) to introduce AI-derived (AID) markers for clinical decision support. We used xAI to decode the outcome of 15,726 patients across 38 solid cancer entities based on 350 markers, including clinical records, image-derived body compositions, and mutational tumor profiles. xAI determined the prognostic contribution of each clinical marker at the patient level and identified 114 key markers that accounted for 90% of the neural network’s decision process. Moreover, xAI enabled us to uncover 1,373 prognostic interactions between markers. Our approach was validated in an independent cohort of 3,288 patients with lung cancer from a US nationwide electronic health record-derived database. These results show the potential of xAI to transform the assessment of clinical variables and enable personalized, data-driven cancer care.

11 January 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PKPhilipp Keyl
Philipp Keyl
PBPhilip Bischoff
Philip Bischoff
GDGabriel Dernbach
Gabriel Dernbach
MBMichael Bockmayr
Michael Bockmayr
RFRebecca Fritz
Rebecca Fritz
FKFrederick Klauschen
Frederick Klauschen
The molecular heterogeneity of cancer cells contributes to the often partial response to targeted therapies and relapse of disease due to the escape of resistant cell populations. While single-cell sequencing has started to improve our understanding of this heterogeneity, it offers a mostly descriptive view on cellular types and states. To obtain more functional insights, we propose scGeneRAI, an explainable deep learning approach that uses layer-wise relevance propagation (LRP) to infer gene regulatory networks from static single-cell RNA sequencing data for individual cells. We benchmark our method with synthetic data and apply it to single-cell RNA sequencing data of a cohort of human lung cancers. From the predicted single-cell networks our approach reveals characteristic network patterns for tumor cells and normal epithelial cells and identifies subnetworks that are observed only in (subgroups of) tumor cells of certain patients. While current state-of-the-art methods are limited by their ability to only predict average networks for cell populations, our approach facilitates the reconstruction of networks down to the level of single cells which can be utilized to characterize the heterogeneity of gene regulation within and across tumors.

7 June 2022 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
PKPhilipp Keyl
Philipp Keyl
MBMichael Bockmayr
Michael Bockmayr
DHDaniel Heim
Daniel Heim
GDGabriel Dernbach
Gabriel Dernbach
GMGrégoire Montavon
Grégoire Montavon
FKFrederick Klauschen
Frederick Klauschen
Understanding the pathological properties of dysregulated protein networks in individual patients’ tumors is the basis for precision therapy. Functional experiments are commonly used, but cover only parts of the oncogenic signaling networks, whereas methods that reconstruct networks from omics data usually only predict average network features across tumors. Here, we show that the explainable AI method layer-wise relevance propagation (LRP) can infer protein interaction networks for individual patients from proteomic profiling data. LRP reconstructs average and individual interaction networks with an AUC of 0.99 and 0.93, respectively, and outperforms state-of-the-art network prediction methods for individual tumors. Using data from The Cancer Proteome Atlas, we identify known and potentially novel oncogenic network features, among which some are cancer-type specific and show only minor variation among patients, while others are present across certain tumor types but differ among individual patients. Our approach may therefore support predictive diagnostics in precision oncology by inferring “patient-level” oncogenic mechanisms.

3 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSimon Schallenberg
Simon Schallenberg
GDGabriel Dernbach
Gabriel Dernbach
SRSharon Ruane
Sharon Ruane
PJPhilipp Sebastian Jurmeister
Philipp Sebastian Jurmeister
CBCornelius Böhm
Cornelius Böhm
FKFrederick Klauschen
Frederick Klauschen
Risk stratification remains a critical challenge in non-small cell lung cancer patients for optimal therapy selection. In this study, we develop an artificial intelligence-powered spatial cellomics approach that combines histology, multiplex immunofluorescence imaging and multimodal machine learning to characterize the complex cellular relationships of 43 cell phenotypes in the tumor microenvironment in a real-world retrospective cohort of 1168 non-small cell lung cancer patients from two large German cancer centers. The model identifies cell niches associated with survival and achieves a 14% and 47% improvement in risk stratification in the two main non-small cell lung cancer subtypes, lung adenocarcinoma and squamous cell carcinoma, respectively, combining niche patterns with conventional cancer staging. Our results show that complex immune cell niche patterns identify potentially undertreated high-risk patients qualifying for adjuvant therapy. Our approach highlights the potential of artificial intelligence powered multiplex imaging analyses to better understand the contribution of the tumor microenvironment to cancer progression and to improve risk stratification and treatment selection in non-small cell lung cancer.

7 August 2025 in NAR Cancer
Verified
Journal Article
Open access
PKPhilipp Keyl
Philipp Keyl
JKJulius Keyl
Julius Keyl
AMAndreas Mock
Andreas Mock
GDGabriel Dernbach
Gabriel Dernbach
LMLiliana H Mochmann
Liliana H Mochmann
FKFrederick Klauschen
Frederick Klauschen
Personalized treatment selection is crucial for cancer patients due to the high variability in drug response. While actionable mutations can increasingly inform treatment decisions, most therapies still rely on population-based approaches. Here, we introduce neural interaction explainable AI (NeurixAI), an explainable and highly scalable deep learning framework that models drug–gene interactions and identifies transcriptomic patterns linked with drug response. Trained on data from 546 646 drug perturbation experiments involving 1135 drugs and molecular profiles from 476 tumors, NeurixAI accurately predicted treatment responses for 272 targeted and 30 chemotherapeutic drugs in unseen tumor samples (Spearman’s rho >0.2), maintaining high performance on an external validation set. Additionally, NeurixAI identified the anticancer potential of 160 repurposed non-cancer drugs. Using explainable artificial intelligence (xAI), our framework uncovered key genes influencing drug response at the individual tumor level and revealed both known and novel mechanisms of drug resistance. These findings demonstrate the potential of integrating transcriptomics with xAI to optimize cancer treatment, enable drug repurposing, and identify new therapeutic targets.

12 October 2023 in medRxiv
Verified
Preprint
Open access
PDF file
JKJulius Keyl
Julius Keyl
PKPhilipp Keyl
Philipp Keyl
GMGrégoire Montavon
Grégoire Montavon
RHRené Hosch
René Hosch
ABAlexander Brehmer
Alexander Brehmer
JKJens Kleesiek
Jens Kleesiek
Despite advances in precision oncology, clinical decision-making still relies on limited parameters and expert knowledge. To address this limitation, we combined multimodal real- world data and explainable artificial intelligence (xAI) to introduce novel AI-derived (AID) markers for clinical decision support. We used deep learning to model the outcome of 15,726 patients across 38 solid cancer entities based on 350 markers, including clinical records, image-derived body compositions, and mutational tumor profiles. xAI determined the prognostic contribution of each clinical marker at the patient level and identified 114 key markers that accounted for 90% of the neural network’s decision process. Moreover, xAI enabled us to uncover 1,373 prognostic interactions between markers. Our approach was validated in an independent cohort of 3,288 lung cancer patients from a US nationwide electronic health record-derived database. These results show the potential of xAI to transform the assessment of clinical parameters and enable personalized, data-driven cancer care.